1604-14-4

Basic information

• Product Name: Ethyl 2,6-dichloroisonicotinate
• Synonyms: Ethyl 2,6-dichloroisonicotinate;Ethyl 2,6-dichloropyridine-4-carboxylate;2,6-Dichloroisonicotinic acid ethyl ester;2,6-Dichloropyridine-4-carboxylic acid ethyl ester;2,6-dichloroisonicotin ethyl ester;4-Pyridinecarboxylic acid, 2,6-dichloro-, ethyl ester
• CAS NO: 1604-14-4
• Molecular Formula: C₈H₇Cl₂NO₂
• Molecular Weight: 220.06
• Product Categories: Pyridines
• Mol File: 1604-14-4.mol
• Article Data: 19

Chemical Properties

• Melting Point: 67 °C
• Boiling Point: 311.4°Cat760mmHg
• Flash Point: 142.2°C
• Appearance: /
• Density: 1.367g/cm³
• Vapor Pressure: 0.000564mmHg at 25°C
• Refractive Index: 1.54
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -4.27±0.10(Predicted)
• CAS DataBase Reference: Ethyl 2,6-dichloroisonicotinate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 2,6-dichloroisonicotinate(1604-14-4)
• EPA Substance Registry System: Ethyl 2,6-dichloroisonicotinate(1604-14-4)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 1604-14-4(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Journal of Medicinal Chemistry, 45, p. 2484, 2002 DOI: 10.1021/jm0200660

InChI:InChI=1/C8H7Cl2NO2/c1-2-13-8(12)5-3-6(9)11-7(10)4-5/h3-4H,2H2,1H3

Upstream product

• 101990-72-1 2,6-dichloro-pyridin-4-ylmethyl chloride 
• 99-11-6 citrazinic acid 
• 75308-46-2 tert-butyl 2,6-dichloropyridine-4-carboxylate 
• 64-17-5 ethanol 
• 7664-93-9 sulfuric acid 
• 5398-44-7 2,6-dichloropyridine-4-carboxylic acid 
• 87486-37-1 3,5-dichloro-1-phenylpyrazin-2(1H)-one 
• 623-47-2 propynoic acid ethyl ester 
• 125850-02-4 3,5-dichloro-2(H)-1,4-oxazin-2-one 
• 42521-08-4 2,6-dichloroisonicotinoyl chloride 

Downstream Products

• 113293-70-2 2,6-dichloropyridine-4-carbaldehyde 
• 1390656-84-4 tert-butyl 4-(4-(7-chloro-4-oxo-3,4-dihydropyrido[3,4-d]pyridazin-5-ylamino)-3-methoxyphenyl)piperazine-1-carboxylate 
• 1390656-69-5 tert-butyl-4-(4-(7-(2,6-dichlorophenylamino)-4-oxo-3,4-dihydropyrido[3,4-d]pyridazin-5-ylamino)-3-methoxyphenyl)piperazine-1-carboxylate 
• 1390655-23-8 7-[(2,6-dichlorophenyl)amino]-5-{[2-methoxy-4-(piperazin-1-yl)phenyl]amino}pyrido[3,4-d]pyridazin-4-ol mono-trifluoroacetate 
• 1390656-76-4 tert-butyl 4-(4-(7-chloro-4-oxo-3,4-dihydropyrido[3,4-d]pyridazin-5-ylamino)-2,5-difluorophenyl)piperazine-1-carboxylate 
• 1390656-77-5 tert-butyl 4-(4-(7-(2,6-dichlorobenzyl)-4-oxo-3,4-dihydropyrido[3,4-d]pyridazin-5-ylamino)-2,5-difluorophenyl)piperazine-1-carboxylate 
• 1390655-34-1 7-(2,6-dichlorobenzyl)-5-{[2,5-difluoro-4-(piperazin-1-yl)phenyl]amino}pyrido[3,4-d]pyridazin-4(3H)-one 
• 1390656-82-2 tert-butyl 4-(4-(7-(2-(isopropylsulfonyl)phenylamino)-4-oxo-3,4-dihydropyrido[3,4-d]pyridazin-5-ylamino)-3-methoxyphenyl)piperazine-1-carboxylate 
• 1390656-85-5 tert-butyl-4-(4-(7-(2-chlorophenylamino)-4-oxo-3,4-dihydropyrido[3,4-d]pyridazin-5-ylamino)-3-methoxyphenyl)piperazine-1-carboxylate 
• 1390655-39-6 7-[(2-chlorophenyl)amino]-5-{[2-methoxy-4-(piperazin-1-yl)phenyl]amino}pyrido[3,4-d]pyridazin-4(3H)-one 
• 1390656-87-7 tert-butyl 4-(4-(7-chloro-4-hydroxypyrido[3,4-d]pyridazin-5-ylamino)-3-fluorophenyl)piperazine-1-carboxylate 
• 1390656-88-8 tert-butyl 4-(4-(7-(2,6-dichlorobenzyl)-4-hydroxypyrido[3,4-d]pyridazin-5-ylamino)-3-fluorophenyl)piperazine-1-carboxylate 
• 1390656-90-2 tert-butyl-4-(4-(7-(2,5-dichlorophenylamino)-4-oxo-3,4-dihydropyrido[3,4-d]pyridazin-5-ylamino)-3-methoxyphenyl)piperazine-1-carboxylate 
• 1390655-43-2 7-[(2,5-dichlorophenyl)amino]-5-{[2-methoxy-4-(piperazin-1-yl)phenyl]amino}pyrido[3,4-d]pyridazin-4(3H)-one 

Relevant articles and documents

FUSED PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROTIC DISEASES

The present invention discloses compounds according to Formula I: Wherein A, B, R1, R2, and Cy are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, pain, and/or abnormal angiogenesis associated diseases by administering the compounds of the invention.

Synthesis and antimicrobial activities of some newly 2,4,6-tri-substituted pyridine derivatives

A series of novel 2-(2-(substituted benzylidene)hydrazinyl)-N'-(substituted benzylidene)-6-chloropyridine-4-carbohydrazide (5a-e), 2-(2- cycloalkylidenehydrazinyl)-6-chloro-N'-cyclo-alkylidenepyridine-4- carbohydrazide (6a,b), 2-(2-(1-(4-substituted phenyl)ethylidene)hydrazinyl)-6- chloro-N'-(1-(4-substituted phenyl)ethylidene)pyridine-4-carbohydrazide (7a,b) and 2-(2-(1-(pyridinyl)ethylidene)hydrazinyl)-6-chloro-N'-(1-(pyridinyl) ethylidene)pyridine-4-carbo-hydrazide (8a-c) derivatives have been synthesized by treating treating 2-chloro-6-hydrazinoisonicotinic acid hydrazide 4 with selected active reagents. Their structures were confirmed by spectral and analytical data. The synthesized compounds were investigated for antimicrobial activities. The antimicrobial screening showed that many of these obtained compounds have good activities comparable to Streptomycin and Fusidic acid as reference drugs. Springer Science+Business Media Dordrecht 2013.

PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS

The invention relates to novel pyridine derivatives of formula (D, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents and the other substituents are as defined in the claims.